Business
CEO Interview
CEO Interview.
About this update from Abingdon Health Plc
[{"type":"text","content":"\n\nAbingdon Health plc\n(\"Abingdon\" or \"the Company\")\n \n \nCEO interview on the Proactive Investors Platform\n \nYork, U.K. 15 March 2024: Abingdon Health plc (AIM: ABDX), a leading international lateral flow contract development and manufacturing organization (CDMO), is pleased to share a recent interview with Chris Yates, CEO of Abingdon, on the Proactive Investors Platform.\n \nWithin this video Chris provides an overview of the financial and operational highlights from Abingdon interim results which were announced on the 14 March 2024.\n \nClick on the link below to watch:\nhttps://www.proactiveinvestors.co.uk/companies/news/1043260/abingdon-health-ceo-discusses-strong-interim-results-robust-pipeline-and-growth-strategy-1043260.html\n \n \nEnquiries\n \n\n\n\n\nAbingdon Health plc\n\n\nwww.abingdonhealth.com/investors/\n\n\n\n\nChris Yates, Chief Executive Officer\n\n\n \n\n\n\n\nChris Hand, Non-Executive Chairman\n\n\n \n\n\n\n\n \n\n\n \n\n\n\n\n \n\n\n \n\n\n\n\nSinger Capital Markets (Sole Broker and Nominated Adviser)\n\n\nTel: +44 (0)20 7496 3000\n\n\n\n\nPeter Steel, Alex Bond (Corporate Finance)\n\n\n \n\n\n\n\nTom Salvesen (Corporate Broking)\n\n\n \n\n\n\n\n\n\n\n \n\n\n\n\n \nAbout Abingdon Health plc\n \nAbingdon Health is a leading lateral flow contract development and manufacturing organisation (CDMO) offering its services to an international customer base across industry sectors that include clinical, animal health, plant health, and environmental testing. Abingdon Health has the internal capabilities to take projects from initial concept through to routine and large-scale manufacturing; from \"idea to commercial success.\"\n \nThe Company's CDMO division offers product development, regulatory support, technology transfer and manufacturing services for customers looking to develop new assays or transfer existing laboratory-based assays to a lateral flow format. Abingdon Health aims to support the increase in need for rapid results across many industries and locations and produces lateral flow tests in areas such as infectious disease, clinical testing including companion diagnostics, animal health and environmental testing. Faster access to results allows for rapid decision making...